The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor

• Main Authors: Sandra S. Hammer, Eleni Beli, Nermin Kady, Qi Wang, Kiana Wood, Todd A. Lydic, Goldis Malek, Daniel R. Saban, Xiaoxin X. Wang, Sugata Hazra, Moshe Levi, Julia V. Busik, Maria B. Grant
• Format: Article
• Language: English
• Published: Elsevier 2017-08-01
• Series: EBioMedicine
• Subjects: Diabetic retinopathy; Dyslipidemia; Liver X receptor; SIRT1; Glucose; Retinal inflammation; Bone marrow; Circulating angiogenic cells; Tumor necrosis factor alpha; Cholesterol metabolism; Reverse cholesterol transport; Cholesterol efflux; Retinal endothelial cells
• Online Access: http://www.sciencedirect.com/science/article/pii/S2352396417302803

Diabetic retinopathy (DR) is a complication secondary to diabetes and is the number one cause of blindness among working age individuals worldwide. Despite recent therapeutic breakthroughs using pharmacotherapy, a cure for DR has yet to be realized. Several clinical trials have highlighted the vital role dyslipidemia plays in the progression of DR. Additionally, it has recently been shown that activation of Liver X receptor (LXRα/LXRβ) prevents DR in diabetic animal models. LXRs are nuclear receptors that play key roles in regulating cholesterol metabolism, fatty acid metabolism and inflammation. In this manuscript, we show insight into DR pathogenesis by demonstrating an innovative signaling axis that unifies key metabolic regulators, Sirtuin 1 and LXR, in modulating retinal cholesterol metabolism and inflammation in the diabetic retina. Expression of both regulators, Sirtuin 1 and LXR, are significantly decreased in diabetic human retinal samples and in a type 2 diabetic animal model. Additionally, activation of LXR restores reverse cholesterol transport, prevents inflammation, reduces pro-inflammatory macrophages activity and prevents the formation of diabetes-induced acellular capillaries. Taken together, the work presented in this manuscript highlights the important role lipid dysregulation plays in DR progression and offers a novel potential therapeutic target for the treatment of DR.